The ph summit "the real world challenge" king’s fund
Written on Friday 8th April 2016
The REAL WORLD Challenge
DEMANDING A MORE TARGETED APPROACH?
Following a successful inaugural conference in 2015, we will be running this event again in 2016, focusing on the challenges associated with measuring the most relevant, robust and persuasive outcomes in ever more targeted patient populations.
The world of pharmaceuticals is changing; innovative targeted medicines are being developed to treat ever more defined pa-tient populations and we have seen a gradual increase in the number of drugs developed for treating rare diseases. The smaller and often more disparate nature of these patient groups can lead to obvious challenges for the generation of much needed RWE including the need for more targeted patient centric outcome measures to sit alongside the traditional clinical outcomes measures.
Join us for this informative and thought provoking session where we will take a fresh look at how we need to better target our RWE efforts to stay ahead in this exciting field.
AGENDA:
Welcome to Session 1 Ever decreasing target patient populations Professor Richard Barker OBE, Director, CASMI Early access/AAR/CDF and the role of RWE Professor Sarah Garner, Associate Director Science Policy and Research NICE Q&A / panel session |
Break |
Welcome to Session 2 Rare Diseases Sebastian Stachowiak General Manager, UK & Ireland, SHIRE Pharmaceuticals Professor Atul Mehta, Consultant Haematologist, Royal Free Hospital The importance of patient centric outcome measures: targeting the patient Professor Nancy J Devlin, Director of Research, Office of Health Economics Q&A / panel session |
Summary, close and drinks |
If you have any queries regarding this event please contact Sam Oliver on 01628 481112 or email events@phassociates.com
PLEASE CONTACT US FOR YOUR PERSONAL INVITE TO REGISTER
